Abstract
Purpose: To evaluate the effect of topical sodium hyaluronate (SH) 0.18% treatment on corneal epithelial healing after epithelial debridement in pars plana vitrectomy in diabetic patients. Method: This is prospective and randomized clinical trial. Our study population included 30 eyes undergoing pars plana vitrectomy that required near total corneal debridement intra-operatively for surgical view. We compared the residual wound and wound healing rate in between 3 groups: 10 diabetic eyes (DMV) on topical SH 0.18%; 10 diabetic eyes (DMC) and 10 non-diabetic eyes (NDM) not treated with topical SH 0.18%. The corneal epithelial wound was measured at 12, 24, 36, 48, 60, 72 and 120 h after the vitrectomy surgery. Results: DMC group had corneal wounds that reepithelialization significantly more slowly than in NDM and DMV groups at 12, 24, 36 and 48 h (Mann–Whitney test p < 0.05). The epithelial healing rate was significantly faster at 12 h in NDM and DMV group (Mann–Whitney test p < 0.05). No differences in the residual epithelial wound and wound healing were detected in between NDM and DMV groups. The mean for epithelial closure in DMC group was delayed 87.6 ± 28.31 h, compared with DMV group (64.8 ± 21.31) and NDM group (56.4 ± 9.88). All groups were followed up 1 month beyond completed wound closure. No recurrent corneal epithelial wound, corneal melting or corneal neovascularization was noted. Conclusion: Diabetic patients on SH 0.18% four times daily for epithelial defect had similar corneal wounds healing rate as non-diabetics. This treatment significantly improved corneal wound healing and accelerated complete corneal wound resurfacing in diabetic patients.
Original language | English |
---|---|
Journal | International Ophthalmology |
DOIs | |
Publication status | Accepted/In press - 1 Jan 2018 |
Fingerprint
Keywords
- Corneal epithelium
- Diabetes
- Hyaluronan
- Sodium hyaluronate (SH)
- Vitrectomy
- Wound healing
ASJC Scopus subject areas
- Ophthalmology
Cite this
Use of commercially available sodium hyaluronate 0.18% eye drops for corneal epithelial healing in diabetic patients. / Ling, Kiet Phang; Bastion, Mae-Lynn Catherine.
In: International Ophthalmology, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of commercially available sodium hyaluronate 0.18% eye drops for corneal epithelial healing in diabetic patients
AU - Ling, Kiet Phang
AU - Bastion, Mae-Lynn Catherine
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Purpose: To evaluate the effect of topical sodium hyaluronate (SH) 0.18% treatment on corneal epithelial healing after epithelial debridement in pars plana vitrectomy in diabetic patients. Method: This is prospective and randomized clinical trial. Our study population included 30 eyes undergoing pars plana vitrectomy that required near total corneal debridement intra-operatively for surgical view. We compared the residual wound and wound healing rate in between 3 groups: 10 diabetic eyes (DMV) on topical SH 0.18%; 10 diabetic eyes (DMC) and 10 non-diabetic eyes (NDM) not treated with topical SH 0.18%. The corneal epithelial wound was measured at 12, 24, 36, 48, 60, 72 and 120 h after the vitrectomy surgery. Results: DMC group had corneal wounds that reepithelialization significantly more slowly than in NDM and DMV groups at 12, 24, 36 and 48 h (Mann–Whitney test p < 0.05). The epithelial healing rate was significantly faster at 12 h in NDM and DMV group (Mann–Whitney test p < 0.05). No differences in the residual epithelial wound and wound healing were detected in between NDM and DMV groups. The mean for epithelial closure in DMC group was delayed 87.6 ± 28.31 h, compared with DMV group (64.8 ± 21.31) and NDM group (56.4 ± 9.88). All groups were followed up 1 month beyond completed wound closure. No recurrent corneal epithelial wound, corneal melting or corneal neovascularization was noted. Conclusion: Diabetic patients on SH 0.18% four times daily for epithelial defect had similar corneal wounds healing rate as non-diabetics. This treatment significantly improved corneal wound healing and accelerated complete corneal wound resurfacing in diabetic patients.
AB - Purpose: To evaluate the effect of topical sodium hyaluronate (SH) 0.18% treatment on corneal epithelial healing after epithelial debridement in pars plana vitrectomy in diabetic patients. Method: This is prospective and randomized clinical trial. Our study population included 30 eyes undergoing pars plana vitrectomy that required near total corneal debridement intra-operatively for surgical view. We compared the residual wound and wound healing rate in between 3 groups: 10 diabetic eyes (DMV) on topical SH 0.18%; 10 diabetic eyes (DMC) and 10 non-diabetic eyes (NDM) not treated with topical SH 0.18%. The corneal epithelial wound was measured at 12, 24, 36, 48, 60, 72 and 120 h after the vitrectomy surgery. Results: DMC group had corneal wounds that reepithelialization significantly more slowly than in NDM and DMV groups at 12, 24, 36 and 48 h (Mann–Whitney test p < 0.05). The epithelial healing rate was significantly faster at 12 h in NDM and DMV group (Mann–Whitney test p < 0.05). No differences in the residual epithelial wound and wound healing were detected in between NDM and DMV groups. The mean for epithelial closure in DMC group was delayed 87.6 ± 28.31 h, compared with DMV group (64.8 ± 21.31) and NDM group (56.4 ± 9.88). All groups were followed up 1 month beyond completed wound closure. No recurrent corneal epithelial wound, corneal melting or corneal neovascularization was noted. Conclusion: Diabetic patients on SH 0.18% four times daily for epithelial defect had similar corneal wounds healing rate as non-diabetics. This treatment significantly improved corneal wound healing and accelerated complete corneal wound resurfacing in diabetic patients.
KW - Corneal epithelium
KW - Diabetes
KW - Hyaluronan
KW - Sodium hyaluronate (SH)
KW - Vitrectomy
KW - Wound healing
UR - http://www.scopus.com/inward/record.url?scp=85058118986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058118986&partnerID=8YFLogxK
U2 - 10.1007/s10792-018-1057-1
DO - 10.1007/s10792-018-1057-1
M3 - Article
AN - SCOPUS:85058118986
JO - International Ophthalmology
JF - International Ophthalmology
SN - 0165-5701
ER -